Nanoparticle medicine specialist Nanoform (Helsinki, Finland) and Boehringer Ingelheim (Ingelheim am Rhein, Germany) will collaborate on proof-of-concept studies related to Nanoform’s CESS technology. The master services agreement enables the two parties to move forward with pre-clinical research related to CESS, an acronym for “Controlled Expansion of Supercritical Solutions.” CESS has the potential to optimize the…